Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment

Kidney International

Volumn 76, Issue 2, 2009, Pages 199-206

  Ashby, Damien R ^a,b   Ford, Heather E ^a   Wynne, Katie J ^a   Wren, Alison M ^a   Murphy, Kevin G ^a   Busbridge, Mark ^a   Brown, Edwina A ^b   Taube, David H ^b   Ghatei, Mohammad A ^a   Tam, Frederick W K ^b   Bloom, Stephen R ^a   Choi, Peter ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Appetite; Dialysis; Energy expenditure; Hormones; Malnutrition; Renal failure

Indexed keywords

GHRELIN;

ADULT; AGED; APPETITE; ARTICLE; BLOOD PRESSURE; CALORIC INTAKE; CIRCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENERGY BALANCE; ENERGY EXPENDITURE; FEMALE; HUMAN; HUNGER; HYPOTHALAMUS; MALE; MALNUTRITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

ADULT; AGED; APPETITE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENERGY INTAKE; ENERGY METABOLISM; FEMALE; GHRELIN; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MALNUTRITION; MIDDLE AGED; RENAL DIALYSIS; YOUNG ADULT;

EID: 67649878152     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.114     Document Type: Article

References (72)

1. Garg AX, Blake PG, Clark WF et al. Association between renal insufficiency and malnutrition in older adults: results from the III NHANES. Kidney Int 2001; 60: 1867-1874.
2. Kopple JD, Greene T, Chumlea WC et al. Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 2000; 57: 1688-1703.
3. Pifer TB, McCullough KP, Port FK et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238-2245.
4. Port FK, Ashby VB, Dhingra RK et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13: 1061-1066.
5. Marcen R, Teruel JL, de la Cal MA et al. The impact of malnutrition in morbidity and mortality in stable haemodialysis patients. Spanish Cooperative Study of Nutrition in Hemodialysis. Nephrol Dial Transplant 1997; 12: 2324-2331.
6. Acchiardo SR, Moore LW, Latour PA. Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int Suppl 1983; 16: S199-S203.
7. Fleischmann E, Teal N, Dudley J et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55: 1560-1567.
8. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
9. Avram MM, Sreedhara R, Fein P et al. Survival on hemodialysis and peritoneal dialysis over 12 years with emphasis on nutritional parameters. Am J Kidney Dis 2001; 37: S77-S80.
10. Mittman N, Avram MM, Oo KK et al. Serum prealbumin predicts survival in hemodialysis and peritoneal dialysis: 10 years of prospective observation. Am J Kidney Dis 2001; 38: 1358-1364.
11. Iseki K, Yamazato M, Tozawa M et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61: 1887-1893.
12. Kamimura MA, Draibe SA, Avesani CM et al. Resting energy expenditure and its determinants in hemodialysis patients. Eur J Clin Nutr 2007; 61: 362-367.
13. Kalantar-Zadeh K, Block G, McAllister CJ et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307.
14. Cheung W, Yu PX, Little BM et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005; 115: 1659-1665.
15. Wren AM, Seal LJ, Cohen MA et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.
16. Cummings DE, Purnell JQ, Frayo RS et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719.
17. Cummings DE, Weigle DS, Frayo RS et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630.
18. le Roux CW, Patterson M, Vincent RP et al. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 2005; 90: 1068-1071.
19. Ashby D, Choi P, Bloom S. Gut hormones and the treatment of disease cachexia. Proc Nutr Soc 2008; 67: 1-7.
20. Wren AM, Small CJ, Ward HL et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141: 4325-4328.
21. Druce MR, Neary NM, Small CJ et al. Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers. Int J Obes (Lond) 2005.
22. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913.
23. Wren AM, Small CJ, Abbott CR et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001; 50: 2540-2547.
24. Wynne K, Giannitsopoulou K, Small CJ et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005; 16: 2111-2118.
25. Sartorio A, Conti A, Ferrero S et al. GH responsiveness to repeated GHRH or hexarelin administration in normal adults. J Endocrinol Invest 1995; 18: 718-722.
26. Caglar K, Fedje L, Dimmitt R et al. Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int 2002; 62: 1054-1059.
27. Kloppenburg WD, Stegeman CA, Hovinga TK et al. Effect of prescribing a high protein diet and increasing the dose of dialysis on nutrition in stable chronic haemodialysis patients: a randomized, controlled trial. Nephrol Dial Transplant 2004; 19: 1212-1223.
28. Dombros NV. Chronic intraperitoneal administration of amino acids does not improve the nutritional status of malnourished continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13(Suppl 2): S487-S490.
29. Cano NJ, Fouque D, Roth H et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18: 2583-2591.
30. Levine JA, Eberhardt NL, Jensen MD. Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 1999; 283: 212-214.
31. Wynne K, Park AJ, Small CJ et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 2006; 30: 1729-1736.
32. Brage S, Brage N, Franks PW et al. Reliability and validity of the combined heart rate and movement sensor Actiheart. Eur J Clin Nutr 2005; 59: 561-570.
33. Crouter SE, Churilla JR, Bassett Jr DR. Accuracy of the Actiheart for the assessment of energy expenditure in adults. Eur J Clin Nutr 2008; 62: 704-711.
34. Asakawa A, Inui A, Kaga T et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001; 120: 337-345.
35. St-Pierre DH, Karelis AD, Cianflone K et al. Relationship between ghrelin and energy expenditure in healthy young women. J Clin Endocrinol Metab 2004; 89: 5993-5997.
36. Chang CC, Hung CH, Yen CS et al. The relationship of plasma ghrelin level to energy regulation, feeding and left ventricular function in non-diabetic haemodialysis patients. Nephrol Dial Transplant 2005; 20: 2172-2177.
37. Yoshimoto A, Mori K, Sugawara A et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 2002; 13: 2748-2752.
38. Asakawa A, Inui A, Fujimiya M et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005; 54: 18-24.
39. Kamegai J, Tamura H, Shimizu T et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 2001; 50: 2438-2443.
40. Nakazato M, Murakami N, Date Y et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
41. Von Roenn JH, Murphy RL, Weber KM et al. Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med 1988; 109: 840-841.
42. Batterham MJ, Garsia R. A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. Int J Androl 2001; 24: 232-240.
43. Vadell C, Segui MA, Gimenez-Arnau JM et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 1998; 21: 347-351.
44. Jatoi A, Rowland K, Loprinzi CL et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22: 2469-2476.
45. Jatoi A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20: 567-573.
46. Oster MH, Enders SR, Samuels SJ et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994; 121: 400-408.
47. Deboer MD, Zhu XX, Levasseur P et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 2007; 148: 3004-3012.
48. Deboer MD, Zhu X, Levasseur PR et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 2008; 149: 827-835.
49. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913.
50. Theander-Carrillo C, Wiedmer P, Cettour-Rose P et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 2006; 116: 1983-1993.
51. Vestergaard ET, Gormsen LC, Jessen N et al. Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of GH-signaling. Diabetes 2008; 57: 3205-3210.
52. Nass R, Pezzoli SS, Oliveri MC et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008; 149: 601-611.
53. Nagaya N, Miyatake K, Uematsu M et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 2001; 86: 5854-5859.
54. Nagaya N, Kojima M, Uematsu M et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1483-R1487.
55. Okumura H, Nagaya N, Enomoto M et al. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 2002; 39: 779-783.
56. Nagaya N, Moriya J, Yasumura Y et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110: 3674-3679.
57. Dixit VD, Schaffer EM, Pyle RS et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66.
58. Li WG, Gavrila D, Liu X et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 2004; 109: 2221-2226.
59. Dembinski A, Warzecha Z, Ceranowicz P et al. Ghrelin attenuates the development of acute pancreatitis in rat. J Physiol Pharmacol 2003; 54: 561-573.
60. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 2006; 130: 1707-1720.
61. Granado M, Priego T, Martin AI et al. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab 2005; 288: E486-E492.
62. Kasimay O, Iseri SO, Barlas A et al. Ghrelin ameliorates pancreaticobiliary inflammation and associated remote organ injury in rats. Hepatol Res 2006; 36: 11-19.
63. Akashi YJ, Springer J, Anker SD. Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. Curr Heart Fail Rep 2005; 2: 198-203.
64. Freeman LM, Roubenoff R. The nutrition implications of cardiac cachexia. Nutr Rev 1994; 52: 340-347.
65. Landbo C, Prescott E, Lange P et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-1861.
66. Cheung WW, Rosengren S, Boyle DL et al. Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int 2008; 74: 180-186.
67. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 2007; 12: 594-600.
68. Druce MR, Wren AM, Park AJ et al. Ghrelin increases food intake in obese as well as lean subjects. Int J Obes Relat Metab Disord 2005; 29: 1130-1136.
69. Wren AM, Seal LJ, Cohen MA et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992.
70. Neary NM, Small CJ, Wren AM et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 2832-2836.
71. Diaz EO, Prentice AM, Goldberg GR et al. Metabolic response to experimental overfeeding in lean and overweight healthy volunteers. Am J Clin Nutr 1992; 56: 641-655.
72. Brage S, Brage N, Franks PW et al. Branched equation modeling of simultaneous accelerometry and heart rate monitoring improves estimate of directly measured physical activity energy expenditure. J Appl Physiol 2004; 96: 343-351.